Olema Pharmaceuticals, Inc.

OLMA - CIK 0001750284

Market cap$855.57 M

Rank#2661

SEC filings538

Olema Pharmaceuticals, Inc. trades as OLMA and has a market capitalization of $855.57 M, making it the #2661 largest US-listed company by market value. This page tracks Olema Pharmaceuticals, Inc. through 538 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Net income (latest FY)-$162.45MFY 2025

Operating cash flow (latest FY)-$146.72MFY 2025

Total assets (latest FY)$533.43MFY 2025

Financial performance

OLMA annual net incomeView details

OLMA operating cash flowView details

Key statistics

Market cap: $855.57 M
Share price (derived)market cap / shares outstanding: $9.79
EPS (diluted)FY 2025: $-1.87
Shares outstandingas of 2026-05-07: 0.09B
Total equityas of 2026-03-31: $480.48M
Return on equity: -33.8%
Cash & equivalentsas of 2026-03-31: $52.55M
Current ratioas of 2026-03-31: 10.88

Latest filings

Filing	Type	Filed
Major company event	8-K	2026-05-26
Major company event	8-K	2026-05-21
SCHEDULE 13G/A	-	2026-05-15
SCHEDULE 13G/A	-	2026-05-15
Quarterly report	10-Q	2026-05-12
Major company event	8-K	2026-05-12
Major company event	8-K	2026-05-01
Insider trade	4	2026-04-29

Browse the full filing history (538 filings)

Recent press releases

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2026-06-02
Olema Oncology – Better medicines for breast cancer and beyond – Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer2026-05-26
Olema Oncology – Better medicines for breast cancer and beyond – Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting2026-05-21
Olema Oncology – Better medicines for breast cancer and beyond – Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
Olema Oncology to Participate in Upcoming Investor Conferences2026-05-19
Olema Oncology – Better medicines for breast cancer and beyond – Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology Reports First Quarter 2026 Financial and Operating Results

Similar companies

The largest companies sharing Olema Pharmaceuticals, Inc.'s SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T OLMA vs LLY

JNJJohnson & Johnson$573.98 B OLMA vs JNJ

ABBVAbbVie Inc.$399.47 B OLMA vs ABBV

MRKMerck & Co., Inc.$293.16 B OLMA vs MRK

AZNAstraZeneca PLC$286.27 B OLMA vs AZN

Frequently asked questions

What is Olema Pharmaceuticals, Inc.'s market cap?

Olema Pharmaceuticals, Inc. (OLMA) has a market capitalization of $855.57 M as of 2026-06-10, ranking #2661 among US-listed companies.

Is Olema Pharmaceuticals, Inc. profitable?

In its latest fiscal year Olema Pharmaceuticals, Inc. reported a net loss of $162.45M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.